| PTC |
Report |
Non-GAAP EPS |
BEAT |
pred ~$1.72 vs. cons $1.60 |
MEDIUM |
| PTC |
Report |
Revenue |
BEAT |
pred ~$628M vs. cons $616M |
MEDIUM |
| PTC |
Report |
Net New ARR |
MISS |
pred ~$43M vs. cons $48M |
LOW |
| PTC |
Guide |
FY26 cc-ARR growth guidance |
UNCHANGED |
guide ~8.5% (midpoint of 7.5%-9.5% reiterated) vs. cons ~8.5% (FY26) |
MEDIUM |
| PTC |
Guide |
FY26 Non-GAAP EPS guidance |
UNCHANGED |
guide ~$7.75 (midpoint of $6.65-$8.90 reiterated) vs. cons ~$7.60 (FY26) |
MEDIUM |
| PTC |
Guide |
Q4 net new ARR / deferred-ARR unlock commentary |
UNKNOWN |
guide ~$0 explicit figure given (qualitative only) vs. cons ~$85M implied Q4 net new ARR (Q4 FY26) |
LOW |
| PTC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| PTC |
Return |
5-day cumulative residual |
-4.5% (FADE) |
Even with a likely EPS/revenue beat driven by favorable renewal duration and buybacks, the core debate—that 2H net-new ARR acceleration leans on previously-banked deferred ARR rather than fresh bookings (management conceded underlying new business is 'approximately' flat y/y)—means sell-side will dissect ARR quality post-print. With FY26 guidance likely reiterated rather than raised, FY27 AI monetization explicitly flagged as 'not overly material,' and a lingering Windchill/FlexPLM security overhang plus a fragile AI/software tape, initial buy-the-beat enthusiasm should fade over the week as analysts trim out-period (Q4/FY27) net-new ARR and margin assumptions, pulling the stock back toward/below pre-print levels. |
MEDIUM |